Refine Search

Search Results -

Terms	Documents
L11	398

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L14

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, June 20, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L14	L11	398	L14
DB=USPT; PLUR=YES; OP=OR			
L13	L11 and (salmine)	2	L13
L12	6624141.pn.	1	L12
L11	L10 and (purified protamine)	398	L11
L10	L9 and l8	1132	L10
L9	L7 and composition	319684	L9
L8	Yang.in.	9812	L8
L7	L6 and (low toxicity)	890473	L7
L6	L5 and (no toxicity)	1039559	L6
L5	L4 and (reduced immunoresponsivenes)	1116711	L5
L4	L3 (low molecular weight heparin)	2250321	L4
L3	L2 and (inactivate heparin)	1355	L3
L2	L1 and (neutralize heparin)	1355	L2
L1	protamine and heparin	1355	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L11 and (salmine)	2

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L13

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, June 20, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L13	L11 and (salmine)	2	L13
L12	6624141.pn.	1	L12
L11	L10 and (purified protamine)	398	L11
L10	L9 and l8	1132	L10
L9	L7 and composition	319684	L9
L8	Yang.in.	9812	L8
L7	L6 and (low toxicity)	890473	L7
L6	L5 and (no toxicity)	1039559	L6
L5	L4 and (reduced immunoresponsivenes)	1116711	L5
L4	L3 (low molecular weight heparin)	2250321	L4
L3	L2 and (inactivate heparin)	1355	L3
L2	L1 and (neutralize heparin)	1355	L2
L1	protamine and heparin	1355	L1

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

First Hit

Search Results - Record(s) 1 through 2 of 2 returned.

1. Document ID: US 6624141 B1

L13: Entry 1 of 2 File: USPT Sep 23, 2003

US-PAT-NO: 6624141
DOCUMENT-IDENTIFIER: US 6624141 B1
** See image for Certificate of Correction **

TITLE: Protamine fragment compositions and methods of use

DATE-ISSUED: September 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yang; Victor C.	Ann Arbor	MI		
Byun; Youngro	Kwangsan-Ku Kwangju			KR

US-CL-CURRENT: 514/2; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

2. Document ID: US 5607567 A

L13: Entry 2 of 2 File: USPT Mar 4, 1997

US-PAT-NO: 5607567
DOCUMENT-IDENTIFIER: US 5607567 A

TITLE: Protamine-responsive polymeric membrane electrode

DATE-ISSUED: March 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yun; Jong H.	Taegu			KR
Meyerhoff; Mark E.	Ann Arbor	MI		
Yang; Victor C.	Ann Arbor	MI		

US-CL-CURRENT: 205/777.5; 204/403.08, 204/403.1, 204/403.14, 204/415, 204/416, 204/418, 205/778, 205/789.5, 205/792.5, 422/82.03, 435/24, 435/287.1, 435/817

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L11 and (salmine)	2

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS JUNE 16 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 23 MAY 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:35:20 ON 20 JUN 2006

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis, biotechds, scisearch
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'MEDLINE' ENTERED AT 14:35:44 ON 20 JUN 2006

FILE 'USPATFULL' ENTERED AT 14:35:44 ON 20 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:35:44 ON 20 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 14:35:44 ON 20 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:35:44 ON 20 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 14:35:44 ON 20 JUN 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 14:35:44 ON 20 JUN 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 14:35:44 ON 20 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 14:35:44 ON 20 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 14:35:44 ON 20 JUN 2006
Copyright (c) 2006 The Thomson Corporation

=> s protamine
L1 29908 PROTAMINE

=> s l1 and purified
L2 6953 L1 AND PURIFIED

=> s l2 and bioactive
L3 645 L2 AND BIOACTIVE

=> s l3 and (not native)
MISSING TERM 'AND (NOT'
The search profile entered contains a left parenthesis,
'(' followed by an operator.

=> s l3 and heparin
L4 423 L3 AND HEPARIN

=> s low molecular weight heparin
L5 28407 LOW MOLECULAR WEIGHT HEPARIN

=> '

' IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

```
=> s l5 and l4
L6          58 L5 AND L4

=> d his

     (FILE 'HOME' ENTERED AT 14:35:20 ON 20 JUN 2006)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS, BIOTECHDS, SCISEARCH' ENTERED AT 14:35:44 ON 20 JUN 2006
L1        29908 S PROTAMINE
L2         6953 S L1 AND PURIFIED
L3          645 S L2 AND BIOACTIVE
L4          423 S L3 AND HEPARIN
L5        28407 S LOW MOLECULAR WEIGHT HEPARIN
L6           58 S L5 AND L4

=> s l6 and (low toxicity)
L7            6 L6 AND (LOW TOXICITY)

=> d l7 ti abs ibib tot

L7   ANSWER 1 OF 6  USPATFULL on STN
TI     Hinge core mimetibodies, compositions, methods and uses
AB     The present invention relates to at least one novel human hinge core
       mimetibody or specified portion or variant, including isolated nucleic
       acids that encode at least one hinge core mimetibody or specified
       portion or variant, hinge core mimetibody or specified portion or
       variants, vectors, host cells, transgenic animals or plants, and methods
       of making and using thereof, including therapeutic compositions, methods
       and devices.

ACCESSION NUMBER:         2006:150969  USPATFULL
TITLE:                    Hinge core mimetibodies, compositions, methods and uses
INVENTOR(S):              Huang, ChiChi, Berwyn, PA, UNITED STATES
                          Heavner, George A., Malvern, PA, UNITED STATES
                          Knight, David M., Berwyn, PA, UNITED STATES
                          Ghrayeb, John, Downingtown, PA, UNITED STATES
                          Scallon, Bernard J., Wayne, PA, UNITED STATES
                          Nesspor, Thomas C., Collegeville, PA, UNITED STATES

                               NUMBER        KIND    DATE
                          --------------- ------ --------
PATENT INFORMATION:       US 2006127404      A1   20060615
APPLICATION INFO.:        US 2004-953613     A1   20040929  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2003-507231P    20030930 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON &
                          JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
NUMBER OF CLAIMS:         23
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       172 Drawing Page(s)
LINE COUNT:               10748

L7   ANSWER 2 OF 6  USPATFULL on STN
TI     Methods and products related to the intracellular delivery of
       polysaccharides
AB     The invention relates, in part, to methods and compositions for the
```

intracellular delivery of polysaccharides. In particular, the methods and compositions relate to the intracellular delivery of glycosaminoglycans, such as **heparin**. The invention in other aspects relates to the use of glycosaminoglycans for the treatment of proliferative disorders, such as cancer. The invention is still other aspects relates to improving cell viability. The invention also relates to the delivery of polysaccharides while avoiding unwanted effects of the polysaccharides. For example, **heparin** can be delivered while avoiding its anticoagulant effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:98545 USPATFULL
TITLE: Methods and products related to the intracellular delivery of polysaccharides
INVENTOR(S): Berry, David A., Brookline, MA, UNITED STATES
Anderson, Daniel G., Framingham, MA, UNITED STATES
Lynn, David M., Madison, WI, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
Langer, Robert S., Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006083711	A1	20060420	
APPLICATION INFO.:	US 2005-107360	A1	20050415	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-562873P	20040415	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 39 Drawing Page(s)
LINE COUNT: 4084
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 6 USPATFULL on STN
TI **Protamine** fragment compositions and methods of use
AB Provided are **bioactive, low-toxicity** **protamine** fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing **heparin** and reducing post-operative bleeding. Improved **protamine** fragment-insulin solutions and methods for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:118259 USPATFULL
TITLE: **Protamine** fragment compositions and methods of use
INVENTOR(S): Yang, Victor C., Ann Arbor, MI, UNITED STATES
Byun, Youngro, Kwangsan-Ku Kwangju, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005101532	A1	20050512	
APPLICATION INFO.:	US 2003-668663	A1	20030923	(10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-700967, filed on 16 Nov 2000, GRANTED, Pat. No. US 6624141 A 371 of International Ser. No. WO 2000-US6876, filed on 15 Mar

2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124873P	19990317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1-47
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 6 USPATFULL on STN
TI Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AB The present invention relates to anti-target immunoglobulin derived proteins, including isolated nucleic acids that encode at least one anti-target Ig derived protein, target, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:38349 USPATFULL
TITLE: Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
INVENTOR(S): Lu, Jin, Boothwyn, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005033029	A1	20050210	
APPLICATION INFO.:	US 2004-872932	A1	20040621	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-483654P	20030630 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 176 Drawing Page(s)
LINE COUNT: 6132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 6 USPATFULL on STN
TI Combination therapy for the treatment of diseases involving inflammatory components
AB Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio- and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:19478 USPATFULL
TITLE: Combination therapy for the treatment of diseases involving inflammatory components
INVENTOR(S): Krause, James E., Madison, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014782	A1	20040122	
APPLICATION INFO.:	US 2003-401113	A1	20030327	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-368925P	20020329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leslie-Anne Horvath, Neurogen Corporation, Patent Department, 35 NE Industrial Road, Branford, CT, 06405
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 9573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 6 USPATFULL on STN
TI **Protamine** fragment compositions and methods of use
AB Provided are **bioactive, low-toxicity** **protamine** fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing **heparin** and reducing post-operative bleeding. Improved **protamine** fragment-insulin solutions and methods for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:253624 USPATFULL
TITLE: **Protamine** fragment compositions and methods of use
INVENTOR(S): Yang, Victor C., Ann Arbor, MI, United States
Byun, Youngro, Kwangsan-Ku Kwangju, KOREA, REPUBLIC OF
PATENT ASSIGNEE(S): The Regents of The University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6624141	B1	20030923	
	WO 2000055196		20000921	
APPLICATION INFO.:	US 2000-700967		20001116	(9)
	WO 1999-US6876		19990309	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124873P	19990317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 14:35:20 ON 20 JUN 2006)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS, BIOTECHDS, SCISEARCH' ENTERED AT 14:35:44 ON 20 JUN 2006
L1         29908 S PROTAMINE
L2          6953 S L1 AND PURIFIED
L3           645 S L2 AND BIOACTIVE
L4           423 S L3 AND HEPARIN
L5         28407 S LOW MOLECULAR WEIGHT HEPARIN
L6            58 S L5 AND L4
L7             6 S L6 AND (LOW TOXICITY)

=> s l6 and ( immunoresponsiveness)
L8            22 L6 AND (IMMUNORESPONSIVENESS)

=> s heparin and (inactivation)
L9          8949 HEPARIN AND (INACTIVATION)

=> s l9 and (protamine)
L10          895 L9 AND (PROTAMINE)

=> s l8 and l10
L11           21 L8 AND L10

=> d l11 ti abs ibib to
'TO' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
             IPCI-2, IPCR, EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
```

```
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR,
             EXF, ARTU, OS, CC, SX, ST, IT
IPC.TAB ---- IPC in tabular format
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2,
             IPCR, EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             IPCI, IPCI-2, IPCR

SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR(random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
ENTER DISPLAY FORMAT (STD):end

=> d his

     (FILE 'HOME' ENTERED AT 14:35:20 ON 20 JUN 2006)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS, BIOTECHDS, SCISEARCH' ENTERED AT 14:35:44 ON 20 JUN 2006
L1         29908 S PROTAMINE
L2          6953 S L1 AND PURIFIED
L3           645 S L2 AND BIOACTIVE
L4           423 S L3 AND HEPARIN
L5         28407 S LOW MOLECULAR WEIGHT HEPARIN
L6            58 S L5 AND L4
L7             6 S L6 AND (LOW TOXICITY)
L8            22 S L6 AND ( IMMUNORESPONSIVENESS)
L9          8949 S HEPARIN AND (INACTIVATION)
L10          895 S L9 AND (PROTAMINE)
L11           21 S L8 AND L10

=> d l11 ti abs ibib tot

L11  ANSWER 1 OF 21  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
```

encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:99621 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006084794	A1	20060420
APPLICATION INFO.:	US 2005-264096	A1	20051102 (11)

RELATED APPLN. INFO.:	Division of Ser. No. US 2001-833245, filed on 12 Apr 2001, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	20 Drawing Page(s)
LINE COUNT:	24280

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:305894 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Ballance, David J., Berwyn, PA, UNITED STATES Sleep, Darrell, West Bridgford, UNITED KINGDOM Prior, Christopher P., Rosemont, PA, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation) Delta Biotechnology Limited (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005266533	A1	20051201
APPLICATION INFO.:	US 2005-78914	A1	20050314 (11)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-832501, filed on 12 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1-60
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:305893 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)
Principia Pharmaceutical Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005266532	A1	20051201
APPLICATION INFO.:	US 2005-78663	A1	20050314 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-833117, filed on 12 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229358P	20000412 (60)
	US 2000-199384P	20000425 (60)
	US 2000-256931P	20001221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1-59
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 12894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid

molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:280980 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005244931	A1	20051103
APPLICATION INFO.:	US 2004-967457	A1	20041019 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 2001-833041, filed on 12 Apr 2001, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1-33
NUMBER OF DRAWINGS:	20 Drawing Page(s)
LINE COUNT:	16289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:236070 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6946134	B1	20050920	
APPLICATION INFO.:	US 2001-833111		20010412	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)

	US 2000-229358P 20000412 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Carlson, Karen Cochrane
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT:	23429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:214989 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES Ballance, David J., Berwyn, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005186664	A1	20050825
APPLICATION INFO.:	US 2004-775204	A1	20040211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)
	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 25129
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 21 USPATFULL on STN
TI **Protamine** fragment compositions and methods of use
AB Provided are **bioactive**, low-toxicity **protamine** fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing **heparin** and reducing post-operative bleeding. Improved **protamine** fragment-insulin solutions and methods for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:118259 USPATFULL
TITLE: **Protamine** fragment compositions and methods of use
INVENTOR(S): Yang, Victor C., Ann Arbor, MI, UNITED STATES
Byun, Youngro, Kwangsan-Ku Kwangju, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005101532	A1	20050512
APPLICATION INFO.:	US 2003-668663	A1	20030923 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-700967, filed on 16 Nov 2000, GRANTED, Pat. No. US 6624141 A 371 of International Ser. No. WO 2000-US6876, filed on 15 Mar 2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124873P	19990317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1-47
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:117724 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005100991	A1	20050512
APPLICATION INFO.:	US 2004-932104	A1	20040902 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:63530 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054570	A1	20050310
APPLICATION INFO.:	US 2004-775180	A1	20040211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US40892, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-360000P	20020228 (60)
	US 2002-378950P	20020510 (60)
	US 2002-398008P	20020724 (60)
	US 2002-411355P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)
	US 2002-350358P	20020124 (60)
	US 2002-359370P	20020226 (60)
	US 2002-367500P	20020327 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)

	US 2002-370227P 20020408 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	32
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Page(s)
LINE COUNT:	20949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:63014 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054051	A1	20050310
APPLICATION INFO.:	US 2004-922142	A1	20040820 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	17526		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:43296 USPATFULL
TITLE:	Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005037022	A1	20050217
APPLICATION INFO.:	US 2004-816042	A1	20040402 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US31794, filed on 4 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-327281P	20011005 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 17090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 21 USPATFULL on STN
TI ALBUMIN FUSION PROTEINS
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:221354 USPATFULL
TITLE: ALBUMIN FUSION PROTEINS
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171123	A1	20040902
	US 6926898	B2	20050809
APPLICATION INFO.:	US 2001-832929	A1	20010412 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 17424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:13611 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010134	A1	20040115	
APPLICATION INFO.:	US 2001-833245	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 21 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219875	A1	20031127	
	US 6905688	B2	20050614	
APPLICATION INFO.:	US 2001-833118	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199043	A1	20031023	
APPLICATION INFO.:	US 2001-832501	A1	20010412	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 21 USPATFULL on STN
TI **Protamine** fragment compositions and methods of use
AB Provided are **bioactive**, low-toxicity **protamine** fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing **heparin** and reducing post-operative bleeding. Improved **protamine** fragment-insulin solutions and methods for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:253624 USPATFULL

TITLE: **Protamine** fragment compositions and methods of use
INVENTOR(S): Yang, Victor C., Ann Arbor, MI, United States
Byun, Youngro, Kwangsan-Ku Kwangju, KOREA, REPUBLIC OF
PATENT ASSIGNEE(S): The Regents of The University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6624141	B1	20030923	
	WO 2000055196		20000921	
APPLICATION INFO.:	US 2000-700967		20001116	(9)
	WO 1999-US6876		19990309	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124873P	19990317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 21 USPATFULL on STN
TI Chemokine beta-1 fusion proteins
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ckβ-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-γ, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143191	A1	20030731	
APPLICATION INFO.:	US 2002-153604	A1	20020524	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 15446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 21 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003125247	A1	20030703
	US 6994857	B2	20060207
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 21 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:99522 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003068627	A1	20030410
APPLICATION INFO.:	US 2002-91458	A1	20020307 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764900, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)

US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20034
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 21 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:171924 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002090673	A1	20020711	
APPLICATION INFO.:	US 2001-764898	A1	20010117	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-179065P	20000131	(60)
	US 2000-180628P	20000204	(60)
	US 2000-214886P	20000628	(60)
	US 2000-217487P	20000711	(60)
	US 2000-225758P	20000814	(60)
	US 2000-220963P	20000726	(60)
	US 2000-217496P	20000711	(60)
	US 2000-225447P	20000814	(60)
	US 2000-218290P	20000714	(60)
	US 2000-225757P	20000814	(60)
	US 2000-226868P	20000822	(60)
	US 2000-216647P	20000707	(60)
	US 2000-225267P	20000814	(60)
	US 2000-216880P	20000707	(60)
	US 2000-225270P	20000814	(60)
	US 2000-251869P	20001208	(60)
	US 2000-235834P	20000927	(60)
	US 2000-234274P	20000921	(60)
	US 2000-234223P	20000921	(60)
	US 2000-228924P	20000830	(60)
	US 2000-224518P	20000814	(60)
	US 2000-236369P	20000929	(60)
	US 2000-224519P	20000814	(60)
	US 2000-220964P	20000726	(60)

	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25258	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.